Date published: 2025-9-9

1-800-457-3801

SCBT Portrait Logo
Seach Input

v-Maf Inhibitors

v-Maf inhibitors belong to a class of chemical compounds that specifically target v-Maf avian musculoaponeurotic fibrosarcoma oncogene homolog proteins, a subgroup of the Maf family of transcription factors. These proteins play a critical role in regulating gene expression and are involved in various cellular processes, including cell differentiation, proliferation, and apoptosis. the vin v-Maf stands for viral, indicating that these proteins were initially discovered as oncogenes in avian retroviruses. In normal physiological conditions, Maf proteins help regulate the expression of genes involved in various cellular functions, but when their activity is dysregulated or overexpressed, it can lead to the development of diseases, including certain types of cancer. v-Maf inhibitors are designed to specifically target and block the activity of v-Maf proteins, thereby modulating their transcriptional activity and preventing the downstream effects of their aberrant activation. These inhibitors can function through various mechanisms, such as interfering with protein-protein interactions, disrupting DNA binding, or affecting post-translational modifications of v-Maf proteins. By inhibiting v-Maf activity, these compounds hold the potential to alter the expression of genes under v-Maf control, which may have implications in the context of cellular differentiation, proliferation, and survival. While their exact applications may vary depending on ongoing research and development, v-Maf inhibitors represent a promising avenue for exploring the molecular mechanisms underlying diseases associated with v-Maf dysregulation and may offer insights into novel strategies for future drug development.

Items 1 to 10 of 13 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

(±)-JQ1

1268524-69-1sc-472932
sc-472932A
5 mg
25 mg
$226.00
$846.00
1
(0)

JQ1 is a bromodomain inhibitor that targets BET (Bromodomain and Extra-Terminal) proteins, disrupting their role in gene transcription.

Nutlin-3

548472-68-0sc-45061
sc-45061A
sc-45061B
1 mg
5 mg
25 mg
$56.00
$212.00
$764.00
24
(1)

Nutlin-3 inhibits MDM2, a protein that degrades p53, potentially counteracting the effects of v-Maf on p53 function.

MLN 4924

905579-51-3sc-484814
1 mg
$280.00
1
(0)

MLN4924 inhibits NEDD8-activating enzyme, which may stabilize v-Maf by disrupting its ubiquitin-dependent degradation.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$132.00
$1064.00
115
(2)

Bortezomib is a proteasome inhibitor that can lead to the accumulation of v-Maf by preventing its proteasomal degradation.

Retinoic Acid, all trans

302-79-4sc-200898
sc-200898A
sc-200898B
sc-200898C
500 mg
5 g
10 g
100 g
$65.00
$319.00
$575.00
$998.00
28
(1)

ATRA can downregulate v-Maf expression, potentially inhibiting its oncogenic activity.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$112.00
$163.00
$928.00
19
(1)

Trametinib inhibits MEK, disrupting signaling pathways that v-Maf may activate, potentially inhibiting its downstream effects.

Tozasertib

639089-54-6sc-358750
sc-358750A
25 mg
50 mg
$61.00
$85.00
4
(1)

Tozasertib inhibits Aurora kinases, affecting cell division and potentially disrupting v-Maf's role in promoting cell proliferation.

Thalidomide

50-35-1sc-201445
sc-201445A
100 mg
500 mg
$109.00
$350.00
8
(0)

Thalidomide has anti-inflammatory and anti-angiogenic properties. Its mechanism against v-Maf is not well-defined but may involve immunomodulation and angiogenesis interference.

Suberoylanilide Hydroxamic Acid

149647-78-9sc-220139
sc-220139A
100 mg
500 mg
$130.00
$270.00
37
(2)

Vorinostat modulates gene expression by affecting histone acetylation, potentially impacting v-Maf's transcriptional regulation.

Romidepsin

128517-07-7sc-364603
sc-364603A
1 mg
5 mg
$214.00
$622.00
1
(1)

Romidepsin, like Vorinostat, can modulate gene expression through histone acetylation, potentially affecting v-Maf's transcriptional regulation.